Chemomab Therapeutics (CMMB) Operating Income (2017 - 2019)

Chemomab Therapeutics' Operating Income history runs 3 years deep, the most recent figure standing at $3.9 million for Q3 2019.

• Quarterly Operating Income rose 55.57% year-over-year to $3.9 million in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $16.8 million (up 40.17% YoY) and the FY2018 annual result came in at -$13.0 million, down 38.88% from the prior year.
• Operating Income was $3.9 million for Q3 2019 at Chemomab Therapeutics, down from $4.4 million in the prior quarter.
• Across five years, Operating Income topped out at $5.4 million in Q1 2019 and bottomed at $1.9 million in Q4 2017.
• A 3-year average of $3.6 million and a median of $3.6 million in 2018 frame the typical range for Operating Income.
• Peak annual rise in Operating Income reached 59.78% in 2019, while the deepest fall reached 6.75% in 2019.
• Chemomab Therapeutics' Operating Income stood at $1.9 million in 2017, then surged by 58.13% to $3.0 million in 2018, then jumped by 30.95% to $3.9 million in 2019.
• Business Quant data shows CMMB's Operating Income at $3.9 million in Q3 2019, $4.4 million in Q2 2019, and $5.4 million in Q1 2019.